CN109316445A - 一种用于牛、羊眼部疾病的喷剂 - Google Patents

一种用于牛、羊眼部疾病的喷剂 Download PDF

Info

Publication number
CN109316445A
CN109316445A CN201811359944.2A CN201811359944A CN109316445A CN 109316445 A CN109316445 A CN 109316445A CN 201811359944 A CN201811359944 A CN 201811359944A CN 109316445 A CN109316445 A CN 109316445A
Authority
CN
China
Prior art keywords
eye disease
spray
acyclovir
taurine
dexamethasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811359944.2A
Other languages
English (en)
Inventor
胡建军
敖维平
刘俊峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarim University
Original Assignee
Tarim University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarim University filed Critical Tarim University
Priority to CN201811359944.2A priority Critical patent/CN109316445A/zh
Publication of CN109316445A publication Critical patent/CN109316445A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：地塞米松0.1‑0.5mg，阿昔洛韦10‑15mg，苯扎氯铵0.02‑0.04mg，牛磺酸10‑15mg，维生素B6 3‑6mg，硫酸软骨素0.5‑1mg，乙醇20ml、纯化水80ml。本发明对牛羊急慢性结膜炎、沙眼、角膜炎、泪囊炎、病毒性角膜炎、虹膜睫状体炎等眼病有非常好的疗效，且可以促进眼角膜的修复。

Description

一种用于牛、羊眼部疾病的喷剂
技术领域
本发明涉及畜牧领域，具体涉及一种用于牛、羊眼部疾病的喷剂。
背景技术
目前，对于牛羊眼部发生的结膜炎病变的情况，大多选用恩诺沙星滴眼液或其他消炎类滴眼液，由于这类滴眼液大多只有杀菌作用，在无法缓解牛羊眼部的不适的同时，对牛羊急慢性结膜炎、沙眼、角膜炎、泪囊炎、病毒性角膜炎、虹膜睫状体炎等眼病的效果较差。
发明内容
为解决上述问题，本发明提供了一种用于牛、羊眼部疾病的喷剂，可以缓解牛羊眼部的不适，且对牛羊急慢性结膜炎、沙眼、角膜炎、泪囊炎、病毒性角膜炎、虹膜睫状体炎等眼病有非常好的疗效。
为实现上述目的，本发明采取的技术方案为：
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.1-0.5mg，阿昔洛韦10-15mg，苯扎氯铵0.02-0.04mg，牛磺酸10-15mg，维生素B6 3-6mg，硫酸软骨素0.5-1mg，乙醇20ml、纯化水80ml。
优选地，由下列药剂按重量比组成：
地塞米松0.1mg，阿昔洛韦10mg，苯扎氯铵0.02mg，牛磺酸10mg，维生素B6 3mg，硫酸软骨素0.5mg，乙醇20ml、纯化水80ml。
优选地，由下列药剂按重量比组成：
地塞米松0.5mg，阿昔洛韦15mg，苯扎氯铵0.04mg，牛磺酸15mg，维生素B6 6mg，硫酸软骨素1mg，乙醇20ml、纯化水80ml。
优选地，由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12.5mg，苯扎氯铵0.03mg，牛磺酸12.5mg，维生素B64.5mg，硫酸软骨素0.75mg，乙醇20ml、纯化水80ml。
优选地，由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12mg，苯扎氯铵0.03mg，牛磺酸12mg，维生素B6 4mg，硫酸软骨素0.7mg，乙醇20ml、纯化水80ml。
优选地，由下列药剂按重量比组成：
地塞米松0.4mg，阿昔洛韦13mg，苯扎氯铵0.03mg，牛磺酸13mg，维生素B6 5mg，硫酸软骨素0.8mg，乙醇20ml、纯化水80ml。
本发明对牛羊急慢性结膜炎、沙眼、角膜炎、泪囊炎、病毒性角膜炎、虹膜睫状体炎等眼病有非常好的疗效，且可以促进眼角膜的修复。
具体实施方式
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明，但不以任何形式限制本发明。应当指出的是，对本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进。这些都属于本发明的保护范围。
实施例1
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.1mg，阿昔洛韦10mg，苯扎氯铵0.02mg，牛磺酸10mg，维生素B6 3mg，硫酸软骨素0.5mg，乙醇20ml、纯化水80ml。
实施例2
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.5mg，阿昔洛韦15mg，苯扎氯铵0.04mg，牛磺酸15mg，维生素B6 6mg，硫酸软骨素1mg，乙醇20ml、纯化水80ml。
实施例3
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12.5mg，苯扎氯铵0.03mg，牛磺酸12.5mg，维生素B64.5mg，硫酸软骨素0.75mg，乙醇20ml、纯化水80ml。
实施例4
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12mg，苯扎氯铵0.03mg，牛磺酸12mg，维生素B6 4mg，硫酸软骨素0.7mg，乙醇20ml、纯化水80ml。
实施例5
一种用于牛、羊眼部疾病的喷剂，由下列药剂按重量比组成：
地塞米松0.4mg，阿昔洛韦13mg，苯扎氯铵0.03mg，牛磺酸13mg，维生素B6 5mg，硫酸软骨素0.8mg，乙醇20ml、纯化水80ml。
本具体实施使用时按实施例1-5所述的配方量取各组分加装在带喷头的塑料瓶内，手动摇匀后，对准牛眼，每只牛眼按一泵，一日三次。基于一周后，牛羊眼睑肿胀的情况以及眼周粘稠丝状分泌物消失，且可以有效改善牛眼睛充血、流泪症状。
以上对本发明的具体实施例进行了描述。需要理解的是，本发明并不局限于上述特定实施方式，本领域技术人员可以在权利要求的范围内做出各种变化或修改，这并不影响本发明的实质内容。在不冲突的情况下，本申请的实施例和实施例中的特征可以任意相互组合。

Claims (6)

1.一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.1-0.5mg，阿昔洛韦10-15mg，苯扎氯铵0.02-0.04mg，牛磺酸10-15mg，维生素B63-6mg，硫酸软骨素0.5-1mg，乙醇20ml、纯化水80ml。
2.如权利要求1所述的一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.1mg，阿昔洛韦10mg，苯扎氯铵0.02mg，牛磺酸10mg，维生素B63mg，硫酸软骨素0.5mg，乙醇20ml、纯化水80ml。
3.如权利要求1所述的一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.5mg，阿昔洛韦15mg，苯扎氯铵0.04mg，牛磺酸15mg，维生素B66mg，硫酸软骨素1mg，乙醇20ml、纯化水80ml。
4.如权利要求1所述的一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12.5mg，苯扎氯铵0.03mg，牛磺酸12.5mg，维生素B64.5mg，硫酸软骨素0.75mg，乙醇20ml、纯化水80ml。
5.如权利要求1所述的一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.3mg，阿昔洛韦12mg，苯扎氯铵0.03mg，牛磺酸12mg，维生素B64mg，硫酸软骨素0.7mg，乙醇20ml、纯化水80ml。
6.如权利要求1所述的一种用于牛、羊眼部疾病的喷剂，其特征在于：由下列药剂按重量比组成：
地塞米松0.4mg，阿昔洛韦13mg，苯扎氯铵0.03mg，牛磺酸13mg，维生素B65mg，硫酸软骨素0.8mg，乙醇20ml、纯化水80ml。
CN201811359944.2A 2018-11-15 2018-11-15 一种用于牛、羊眼部疾病的喷剂 Pending CN109316445A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811359944.2A CN109316445A (zh) 2018-11-15 2018-11-15 一种用于牛、羊眼部疾病的喷剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811359944.2A CN109316445A (zh) 2018-11-15 2018-11-15 一种用于牛、羊眼部疾病的喷剂

Publications (1)

Publication Number Publication Date
CN109316445A true CN109316445A (zh) 2019-02-12

Family

ID=65257672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811359944.2A Pending CN109316445A (zh) 2018-11-15 2018-11-15 一种用于牛、羊眼部疾病的喷剂

Country Status (1)

Country Link
CN (1) CN109316445A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119448A1 (en) * 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
CN101342180A (zh) * 2008-08-21 2009-01-14 武汉远大制药集团有限公司 一种眼用药物组合物及其制备方法
CN101564374A (zh) * 2008-04-25 2009-10-28 北京和润创新医药科技发展有限公司 一种药物眼用即型凝胶
CN102441001A (zh) * 2011-12-13 2012-05-09 江西珍视明药业有限公司 一种复方尿维氨滴眼液及其制备方法
CN107073008A (zh) * 2014-11-07 2017-08-18 参天制药株式会社 眼科用水性组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119448A1 (en) * 2006-11-02 2008-05-22 Friedlaender Mitchell H Methods of treating an ocular allergy with low dose dexamethasone
CN101564374A (zh) * 2008-04-25 2009-10-28 北京和润创新医药科技发展有限公司 一种药物眼用即型凝胶
CN101342180A (zh) * 2008-08-21 2009-01-14 武汉远大制药集团有限公司 一种眼用药物组合物及其制备方法
CN102441001A (zh) * 2011-12-13 2012-05-09 江西珍视明药业有限公司 一种复方尿维氨滴眼液及其制备方法
CN107073008A (zh) * 2014-11-07 2017-08-18 参天制药株式会社 眼科用水性组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
王晓波: "《药物运释系统》", 31 August 2007, 中国医药科技出版社 *
覃洪，黄春平: "《常用非处方药用药指南》", 30 June 2016, 广西科学技术出版社 *
谢宗泽: "42例阿昔洛韦联合地塞米松治疗单疱病毒性角膜炎", 《广西医学》 *
陆豪，李海生: "《临床眼科诊治手册》", 30 June 2006, 上海世界图书出版公司 *

Similar Documents

Publication Publication Date Title
DOP2007000093A (es) Antagonistas de los receptores cgrp monocíclicos sustituidos
Kini et al. Role of vitamin C as an antioxidant in cadmium chloride induced testicular damage.
CN109316445A (zh) 一种用于牛、羊眼部疾病的喷剂
MX2007011300A (es) Solucion mejorada de bimatoprost oftalmico.
ZA200504528B (en) Gaming machine
TW200633712A (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
HRP20220762T1 (hr) Upotreba pilokarpin-hidroklorida u liječenju prezbiopije
RU2017139870A (ru) Новые агонисты npr-b
WO2021126320A9 (en) Treatment of amyotrophic lateral sclerosis and related disorders
BRPI0510718A (pt) medicamento para o tratamento de infecções fúngicas, particularmente a aspergilose
WO2014197524A3 (en) Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
CN100482807C (zh) 一种环保水浴脱毛方法
MX2020009348A (es) Composicion de glp-1 para el tratamiento de la obesidad y el control del peso.
DE60023304D1 (de) Peroxovanadiumverbindungen als protein tyrosin phosphatase (ptp) inhibitore: ihre inhibierende wirkung auf angiogenesis, restenosis und die produktion von endothelinen.
Hichem et al. Study of a Culicidian stand in the El Marsa wetlands of the Skikda region
CN208331903U (zh) 一种防落叶积水的投光灯
MX2022005440A (es) Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).
RU2008120070A (ru) Способ экономии витаминов в рационе перепелов
EP2606094A4 (en) SALT-RESISTANT POLYAMIDE COMPOSITIONS
RU2015102000A (ru) Комплексы на основе хондроитина для чрескожного всасывания
CN107898691A (zh) 一种环保洗发水
Wang et al. Role of amyloid β in age-related macular degeneration
CN208091314U (zh) 组合式催泪盾牌
CN107151800A (zh) 一种金属材料脱脂剂
CN207316763U (zh) 一种可伸缩庭院灯

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190212